Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.0K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.0K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.8K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.8K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

591
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
591
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K
Inhaled Medications01:23

Inhaled Medications

936
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
936
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.9K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Raising Medicaid Rebates For Drugs With Accelerated Approval.

Health affairs (Project Hope)·2021
Same author

Payer-Specific Negotiated Prices for Prescription Drugs at Top-Performing US Hospitals.

JAMA internal medicine·2021
Same author

How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?

AMA journal of ethics·2021
Same author

Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic.

Journal of general internal medicine·2021
Same author

Value-based pricing of drugs with multiple indications or in combinations - lessons from Europe.

Nature reviews. Clinical oncology·2021
Same author

Mitigating bias in machine learning for medicine.

Communications medicine·2021

Related Experiment Video

Updated: Mar 10, 2026

Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms
02:34

Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms

Published on: May 10, 2024

2.1K

Fluticasone- vs Budesonide-Based Dual Therapy for COPD.

William B Feldman1,2,3,4, Vidya L Ambati1, Samy Suissa5

  • 1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

JAMA Network Open
|March 9, 2026
PubMed
Summary

Once-daily fluticasone furoate-vilanterol inhalers showed a reduced risk of COPD exacerbations compared to other inhaled corticosteroid-long-acting beta-agonist inhalers. Pneumonia hospitalization risks were similar across all treatments studied.

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.6K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.6K

Related Experiment Videos

Last Updated: Mar 10, 2026

Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms
02:34

Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms

Published on: May 10, 2024

2.1K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.6K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.6K

Area of Science:

  • Pulmonary Medicine and Pharmacology
  • Clinical Outcomes Research
  • Health Services Research

Background:

  • Inhaled corticosteroid-long-acting beta-agonist (ICS-LABA) inhalers are standard for COPD management.
  • Therapeutic equivalence is often assumed, but environmental impact (greenhouse gas emissions) and potential clinical outcome differences exist between dry powder and metered-dose inhalers.
  • This study investigates clinical outcome variations among different ICS-LABA formulations.

Purpose of the Study:

  • To compare COPD exacerbations and pneumonia hospitalizations among three ICS-LABA inhaler types in adults with COPD.
  • To analyze outcomes associated with once-daily fluticasone furoate-vilanterol (dry powder), twice-daily fluticasone propionate-salmeterol (dry powder), and twice-daily budesonide-formoterol (metered-dose) inhalers.

Main Methods:

  • A longitudinal cohort study utilizing US commercial claims data.
  • Propensity score matching (1:1) created three comparison cohorts of new ICS-LABA users aged 40+ with COPD.
  • Primary outcomes: moderate/severe COPD exacerbation and pneumonia hospitalization, analyzed using Cox proportional hazards regression.

Main Results:

  • Fluticasone furoate-vilanterol was associated with a 9% lower risk of exacerbations versus budesonide-formoterol (HR, 0.91; 95% CI, 0.88-0.94) and a 6% lower risk versus fluticasone propionate-salmeterol (HR, 0.94; 95% CI, 0.89-0.98).
  • No significant difference in exacerbation risk was found between fluticasone propionate-salmeterol and budesonide-formoterol (HR, 0.98; 95% CI, 0.95-1.01).
  • No significant differences in pneumonia hospitalization risk were observed across any of the compared ICS-LABA inhaler groups.

Conclusions:

  • Once-daily fluticasone furoate-vilanterol dry powder inhalers demonstrated slightly improved clinical outcomes regarding COPD exacerbations compared to twice-daily budesonide-formoterol metered-dose and fluticasone propionate-salmeterol dry powder inhalers.
  • The study highlights potential intraclass differences in ICS-LABA efficacy for COPD management.
  • Further research is warranted to fully elucidate these intraclass variations and their clinical implications.